Kyowa Kirin subsidiary Kyowa Kirin EMEA has received approval from the European Commission (EC) to expand the use of Crysvita (burosumab) for treating X-linked hypophosphataemia (XLH) in infants aged one month to one year across the EU and European Economic Area.
“We were grateful for the opportunity to present the clinical data package for our mRNA vaccine against COVID-19 to the FDA’s advisory committee today. We thank the committee
This sBLA is based on data from the pivotal Phase 3 KEYNOTE-590 trial, in which KEYTRUDA plus chemotherapy demonstrated significant improvements in the primary endpoints – overall survival
These positive results were observed in the mismatch repair proficient (pMMR) subgroup and the intention-to-treat (ITT) study population, which includes both patients with endometrial carcinoma that is pMMR
Harnessing CN Bio’s Organ-on-a-Chip technology, the aim of the research is to develop a model capable of recapitulating the fibrosis and tissue remodelling seen in chronic interstitial lung
Based in New York, Prevail develops and commercialises disease-modifying Adeno-associated viruses (AAV) based gene therapies to treat neurodegenerative diseases. Under the deal, Eli Lilly will acquire Prevail by paying
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.
